Fundraising Fox
VALANX
2 known investors
Find your way into VALANX
Sign up to see every warm intro you have to VALANX
- Paths you didn't know you had: your email and LinkedIn already hold routes to the VALANX team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
VALANX Biotech develops a site-specific protein conjugation technology (GoldenSite) using click-chemistry to produce homogeneous antibody-drug conjugates with optimized conjugation sites. It targets biopharma developers building next-generation ADCs, aiming to widen therapeutic windows and reduce off-target toxicity.
Founders & leadership
KO
Klaus OrlingerChief Scientific OfficerHe has led R&D teams in pharmaceutical development, advancing drug candidates in immunooncology and infectious diseases through phase I/II trials, and previously helped build a biotech company from early stage through IPO.
Investors · 2
SOSVlisted by SOSVNew York · $30K – $550K
How we know: a partner's Signal profile · funding news · press coverage · sosv.com · Not right? Tell us
xista science ventureslisted by xista science venturesKlosterneuburg · $162K – $4.3M
How we know: xista science ventures's portfolio page · funding news · press coverage · Not right? Tell us
Frequently asked questions
- What does VALANX do?
- VALANX Biotech develops a site-specific protein conjugation technology (GoldenSite) using click-chemistry to produce homogeneous antibody-drug conjugates with optimized conjugation sites. It targets biopharma developers building next-generation ADCs, aiming to widen therapeutic windows and reduce off-target toxicity.
- Who founded VALANX?
- VALANX was founded by Michael Lukesch, Georg Altenbacher.
- Who are VALANX's investors?
- VALANX's investors include SOSV, xista science ventures.